STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] Elevation Oncology, Inc. Common stock SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Several Frazier Life Sciences funds and named individuals filed a Schedule 13G/A reporting that they hold no beneficial ownership of Elevation Oncology common stock. Each Reporting Person discloses 0.00 shares and 0.0% of the class, with zero sole or shared voting power and zero sole or shared dispositive power. The statement includes a certification that the securities were not acquired for the purpose of changing or influencing control of the issuer.

The filing identifies the reporting entities as multiple Frazier Life Sciences partnerships and affiliated entities and names the Members as James N. Topper, Patrick J. Heron, Albert Cha, James Brush and Daniel Estes. A Joint Filing Agreement is incorporated by reference. Given the reported aggregate ownership of zero, this disclosure does not change the companys ownership or voting structure.

Positive
  • All Reporting Persons report 0.00 shares, representing 0.0% of the class
  • Filing includes a certification that the securities were not acquired to influence control
Negative
  • None.

Insights

TL;DR: Routine Schedule 13G/A showing no holdings; no material ownership change.

The filing reports that each Reporting Person holds 0.00 shares and 0.0% of the class, with no sole or shared voting or dispositive powers. From a market-impact perspective, a disclosure of zero ownership is a routine compliance filing that provides transparency but conveys no change to ownership stakes or voting influence. The incorporated Joint Filing Agreement documents the procedural relationship among the filers. Overall, there is no quantitative basis in this statement for a material effect on capitalization, control, or governance of the issuer.

TL;DR: Joint filing by Frazier entities confirms zero holdings and explicitly denies intent to influence control.

The Reporting Persons explicitly state they possess 0.00 shares and 0.0% ownership and include a certification that the positions were not acquired to influence control. For governance analysis, the absence of holdings means these filers do not introduce voting blocs or control dynamics via this filing. The joint filing and the incorporated exhibit document coordination for disclosure purposes, but they do not indicate any exercised or potential control rights based on the information provided.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Frazier Life Sciences Public Fund, L.P.
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:08/14/2025
FHMLSP, L.P.
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:08/14/2025
FHMLSP, L.L.C.
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLSP, L.L.C.
Date:08/14/2025
Frazier Life Sciences Public Overage Fund, L.P.
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P.
Date:08/14/2025
FHMLSP Overage, L.P.
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P.
Date:08/14/2025
FHMLSP Overage, L.L.C.
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C.
Date:08/14/2025
Frazier Life Sciences X, L.P.
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
Date:08/14/2025
FHMLS X, L.P.
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Date:08/14/2025
FHMLS X, L.L.C.
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLS X, L.L.C.
Date:08/14/2025
Frazier Life Sciences XI, L.P.
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:08/14/2025
FHMLS XI, L.P.
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:08/14/2025
FHMLS XI, L.L.C.
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLS XI, L.L.C.
Date:08/14/2025
James N. Topper
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Date:08/14/2025
Patrick J. Heron
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Date:08/14/2025
Albert Cha
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
Date:08/14/2025
James Brush
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
Date:08/14/2025
Daniel Estes
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022
Date:08/14/2025
Exhibit Information

Exhibit 99.1 Joint Filing Agreement, dated as of July 15, 2024, incorporated by reference into this Statement.

FAQ

What ownership stake do the Frazier reporting persons disclose in ELEV?

0.00 shares, representing 0.0% of the class

Who are the primary reporting persons named in the Schedule 13G/A for ELEV?

Several Frazier Life Sciences entities and Members: James N. Topper, Patrick J. Heron, Albert Cha, James Brush and Daniel Estes

Does the filing indicate an intent to influence control of Elevation Oncology (ELEV)?

No. The filing includes a certification that the securities were not acquired to change or influence control

Is this a joint filing among the Reporting Persons for ELEV?

Yes. A Joint Filing Agreement is incorporated by reference into the statement

Does the Schedule 13G/A disclose any voting or dispositive power by the filers over ELEV shares?

No. The filers report zero sole and zero shared voting power and zero sole and zero shared dispositive power
Elevation Oncolo

NASDAQ:ELEV

ELEV Rankings

ELEV Latest News

ELEV Latest SEC Filings

ELEV Stock Data

21.63M
53.04M
0.36%
59.73%
3.51%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON